2024 Q3 Form 10-Q Financial Statement
#000157056224000116 Filed on July 31, 2024
Income Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| Revenue | $61.09M | $66.91M |
| YoY Change | 22.12% | 35.59% |
| Cost Of Revenue | $18.22M | $19.08M |
| YoY Change | 18.09% | 29.67% |
| Gross Profit | $42.86M | $47.83M |
| YoY Change | 23.92% | 38.11% |
| Gross Profit Margin | 70.17% | 71.49% |
| Selling, General & Admin | $52.51M | $50.15M |
| YoY Change | 21.18% | 21.81% |
| % of Gross Profit | 122.5% | 104.85% |
| Research & Development | $2.314M | $2.350M |
| YoY Change | 45.81% | -58.4% |
| % of Gross Profit | 5.4% | 4.91% |
| Depreciation & Amortization | $1.087M | $1.427M |
| YoY Change | -17.09% | 14.43% |
| % of Gross Profit | 2.54% | 2.98% |
| Operating Expenses | $54.82M | $52.50M |
| YoY Change | 22.05% | 9.22% |
| Operating Profit | -$15.47M | -$7.702M |
| YoY Change | 15.13% | -42.68% |
| Interest Expense | -$3.836M | -$3.667M |
| YoY Change | -201.32% | 21.5% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $273.0K | $62.00K |
| YoY Change | 1200.0% | 226.32% |
| Pretax Income | -$19.04M | -$11.31M |
| YoY Change | 12.65% | -37.59% |
| Income Tax | $134.0K | $43.00K |
| % Of Pretax Income | ||
| Net Earnings | -$19.17M | -$11.35M |
| YoY Change | 13.28% | -37.43% |
| Net Earnings / Revenue | -31.38% | -16.96% |
| Basic Earnings Per Share | -$0.30 | -$0.18 |
| Diluted Earnings Per Share | -$0.30 | -$0.18 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 63.09M shares | 62.61M shares |
| Diluted Shares Outstanding | 63.15M shares | 62.72M shares |
Balance Sheet
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $85.04M | $93.67M |
| YoY Change | 119.73% | 124.6% |
| Cash & Equivalents | $85.04M | $93.67M |
| Short-Term Investments | ||
| Other Short-Term Assets | $2.393M | $2.426M |
| YoY Change | 52.52% | -58.88% |
| Inventory | $14.89M | $13.38M |
| Prepaid Expenses | $3.399M | $5.507M |
| Receivables | $44.64M | $43.15M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $150.4M | $158.1M |
| YoY Change | 63.44% | 63.94% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $2.314M | $2.284M |
| YoY Change | 8.64% | -41.07% |
| Goodwill | $21.21M | $21.21M |
| YoY Change | 0.0% | 0.0% |
| Intangibles | $46.59M | $46.28M |
| YoY Change | 0.18% | -1.99% |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $858.0K | $409.0K |
| YoY Change | 286.49% | 83.41% |
| Total Long-Term Assets | $79.25M | $75.64M |
| YoY Change | 4.31% | 4.3% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $150.4M | $158.1M |
| Total Long-Term Assets | $79.25M | $75.64M |
| Total Assets | $229.6M | $233.8M |
| YoY Change | 36.7% | 38.34% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $13.84M | $10.28M |
| YoY Change | 17.65% | 31.22% |
| Accrued Expenses | $34.95M | $32.79M |
| YoY Change | 30.83% | 97.63% |
| Deferred Revenue | $13.23M | $11.79M |
| YoY Change | 50.69% | 31.85% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $60.82M | $54.12M |
| YoY Change | 25.29% | 30.88% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $121.2M | $120.9M |
| YoY Change | 27.45% | 27.51% |
| Other Long-Term Liabilities | $41.67M | $39.39M |
| YoY Change | -4.65% | -0.89% |
| Total Long-Term Liabilities | $162.9M | $160.3M |
| YoY Change | 17.34% | 19.12% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $60.82M | $54.12M |
| Total Long-Term Liabilities | $162.9M | $160.3M |
| Total Liabilities | $223.7M | $214.5M |
| YoY Change | 19.42% | 21.89% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$602.6M | -$583.4M |
| YoY Change | 10.14% | 10.04% |
| Common Stock | $1.000K | $1.000K |
| YoY Change | 0.0% | 0.0% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $5.890M | $19.31M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $229.6M | $233.8M |
| YoY Change | 36.7% | 38.34% |
Cashflow Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$19.17M | -$11.35M |
| YoY Change | 13.28% | -37.43% |
| Depreciation, Depletion And Amortization | $1.087M | $1.427M |
| YoY Change | -17.09% | 14.43% |
| Cash From Operating Activities | -$5.722M | -$6.470M |
| YoY Change | 521.96% | -51.39% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $1.410M | $1.254M |
| YoY Change | 161.11% | 480.56% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | -$1.410M | -$1.254M |
| YoY Change | 161.11% | 480.56% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -1.416M | 4.481M |
| YoY Change | -0.28% | -81.19% |
| NET CHANGE | ||
| Cash From Operating Activities | -5.722M | -6.470M |
| Cash From Investing Activities | -1.410M | -1.254M |
| Cash From Financing Activities | -1.416M | 4.481M |
| Net Change In Cash | -8.548M | -3.243M |
| YoY Change | 196.81% | -131.5% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$5.722M | -$6.470M |
| Capital Expenditures | $1.410M | $1.254M |
| Free Cash Flow | -$7.132M | -$7.724M |
| YoY Change | 388.49% | -42.9% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
56920260 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
60760958 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
60760958 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
56699145 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
56699145 | shares | |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
18443000 | usd |
| CY2024Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4169000 | usd |
| CY2024Q2 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
11789000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
11033000 | usd |
| CY2024Q2 | eols |
Rebates And Coupons Credits And Payments
RebatesAndCouponsCreditsAndPayments
|
9368000 | usd |
| eols |
Rebates And Coupons Credits And Payments
RebatesAndCouponsCreditsAndPayments
|
17996000 | usd | |
| CY2024Q2 | eols |
Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability
PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability
|
6335000 | usd |
| eols |
Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability
PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability
|
17288000 | usd | |
| CY2023Q2 | eols |
Rebates And Coupons Credits And Payments
RebatesAndCouponsCreditsAndPayments
|
8276000 | usd |
| eols |
Rebates And Coupons Credits And Payments
RebatesAndCouponsCreditsAndPayments
|
15502000 | usd | |
| CY2023Q2 | eols |
Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability
PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability
|
6319000 | usd |
| eols |
Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability
PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability
|
15571000 | usd | |
| us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
9765000 | usd | |
| us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
7689000 | usd | |
| CY2024Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
2059000 | usd |
| CY2023Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
1490000 | usd |
| CY2024Q2 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
582000 | usd |
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
770000 | usd | |
| CY2024Q2 | eols |
Accounts Receivable Allowance For Credit Loss Write Off Recovery
AccountsReceivableAllowanceForCreditLossWriteOffRecovery
|
302000 | usd |
| eols |
Accounts Receivable Allowance For Credit Loss Write Off Recovery
AccountsReceivableAllowanceForCreditLossWriteOffRecovery
|
201000 | usd | |
| CY2023Q2 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
69000 | usd |
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
342000 | usd | |
| CY2023Q2 | eols |
Accounts Receivable Allowance For Credit Loss Write Off Recovery
AccountsReceivableAllowanceForCreditLossWriteOffRecovery
|
103000 | usd |
| eols |
Accounts Receivable Allowance For Credit Loss Write Off Recovery
AccountsReceivableAllowanceForCreditLossWriteOffRecovery
|
103000 | usd | |
| CY2023Q2 | eols |
License Supply And Distribution Agreement Minimum Milestone Payment
LicenseSupplyAndDistributionAgreementMinimumMilestonePayment
|
16200000 | eur |
| CY2023Q2 | eols |
License Supply And Distribution Agreement Initial Payment In Connection With Agreement
LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement
|
4100000 | eur |
| CY2023Q2 | eols |
License Supply And Distribution Agreement Initial Payment Due Period
LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod
|
P30D | |
| CY2023Q2 | eols |
License Supply And Distribution Agreement Annual Payment Year One
LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne
|
1600000 | eur |
| CY2023Q2 | eols |
License Supply And Distribution Agreement Annual Payment Year Two
LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo
|
4100000 | eur |
| CY2023Q2 | eols |
License Supply And Distribution Agreement Annual Payment Year Three
LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree
|
3200000 | eur |
| CY2023Q2 | eols |
License Supply And Distribution Agreement Annual Payment Year Four
LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour
|
3200000 | eur |
| CY2023Q2 | eols |
Research And Development In Process1
ResearchAndDevelopmentInProcess1
|
4441000 | usd |
| CY2023Q2 | eols |
License Supply And Distribution Agreement Initial Term
LicenseSupplyAndDistributionAgreementInitialTerm
|
P15Y | |
| CY2023Q2 | eols |
License Supply And Distribution Agreement Renewal Term
LicenseSupplyAndDistributionAgreementRenewalTerm
|
P5Y | |
| CY2023Q2 | eols |
Research And Development In Process1
ResearchAndDevelopmentInProcess1
|
4441000 | usd |
| CY2023 | eols |
Non Cash In Research And Development In Process Expenses
NonCashInResearchAndDevelopmentInProcessExpenses
|
4429000 | usd |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
62724604 | shares |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
62724604 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
56920260 | shares |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-20689000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
46794000 | usd |
| CY2024Q1 | eols |
Stock Issued During Period Value Incentive Equity Plan
StockIssuedDuringPeriodValueIncentiveEquityPlan
|
487000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5090000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13109000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-130000 | usd |
| CY2024Q2 | eols |
Stock Issued During Period Value Incentive Equity Plan
StockIssuedDuringPeriodValueIncentiveEquityPlan
|
2300000 | usd |
| CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5796000 | usd |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11350000 | usd |
| CY2024Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-44000 | usd |
| CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
19314000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-24459000 | usd | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-32931000 | usd | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2836000 | usd | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2449000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
10863000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7465000 | usd | |
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
770000 | usd | |
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
342000 | usd | |
| us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
301000 | usd | |
| us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
424000 | usd | |
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
559000 | usd | |
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
577000 | usd | |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
2000 | usd | |
| us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | usd | |
| us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
3183000 | usd | |
| us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
3330000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
13390000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
6890000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-3749000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
5610000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-193000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
395000 | usd | |
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
70000 | usd | |
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-77000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-246000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
3425000 | usd | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1023000 | usd | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-610000 | usd | |
| us-gaap |
Payments For Legal Settlements
PaymentsForLegalSettlements
|
0 | usd | |
| us-gaap |
Payments For Legal Settlements
PaymentsForLegalSettlements
|
5000000 | usd | |
| eols |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-353000 | usd | |
| eols |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-550000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17085000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-33897000 | usd | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
721000 | usd | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
235000 | usd | |
| us-gaap |
Payments For Software
PaymentsForSoftware
|
1330000 | usd | |
| us-gaap |
Payments For Software
PaymentsForSoftware
|
492000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-2051000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-727000 | usd | |
| eols |
Payments Of Contingent Royalty Obligation
PaymentsOfContingentRoyaltyObligation
|
3607000 | usd | |
| eols |
Payments Of Contingent Royalty Obligation
PaymentsOfContingentRoyaltyObligation
|
2559000 | usd | |
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
0 | usd | |
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
25000000 | usd | |
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
0 | usd | |
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
38000 | usd | |
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
248000 | usd | |
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | usd | |
| eols |
Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan
ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan
|
2787000 | usd | |
| eols |
Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan
ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan
|
135000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
50143000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
22538000 | usd | |
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-174000 | usd | |
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-131000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
30833000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-12217000 | usd | |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
62838000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
53922000 | usd |
| CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93671000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
41705000 | usd |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
8838000 | usd | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
5390000 | usd | |
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
164000 | usd | |
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
56000 | usd | |
| CY2024Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7702000 | usd |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-16624000 | usd | |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11350000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-24459000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17085000 | usd | |
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
93671000 | usd |
| CY2024Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-583438000 | usd |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements, inventory valuations and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company’s actual results could differ materially from those estimates.</span></div> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an agreement (as amended, the “Daewoong Agreement”) with Daewoong Pharmaceutical Co. Ltd. (“Daewoong”), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, New Zealand, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019 and in Canada through its distribution partner in October 2019. The Company also began commercially launching Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe in September 2022 and, as such, has a limited history of sales in those markets. If any previously granted approval to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is retracted or the Company is denied approval or approval is delayed by regulators in any other jurisdictions, it may have a material adverse impact on the Company’s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company’s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, its ability to obtain regulatory approval for Evolysse™, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by aesthetic practitioners and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption and volatility in the global capital markets, including caused by other events, such as public health crises, increased inflation and rising interest rates, and geopolitical conflicts, including the military conflict between Russia and Ukraine and the ongoing conflict in the Middle East, may increase the Company’s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. Substantially all of the Company’s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company’s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</span></div> | ||
| us-gaap |
Number Of Reporting Units
NumberOfReportingUnits
|
1 | reporting_unit | |
| CY2024Q2 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | usd |
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | usd | |
| CY2023Q2 | us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | usd |
| us-gaap |
Goodwill Impairment Loss
GoodwillImpairmentLoss
|
0 | usd | |
| CY2024Q2 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
0 | usd |
| us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
0 | usd | |
| CY2023Q2 | us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
0 | usd |
| us-gaap |
Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
|
0 | usd | |
| CY2024Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
43000 | usd |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
23000 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
90000 | usd | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
46000 | usd | |
| CY2024Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
44779000 | usd |
| CY2023Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
46650000 | usd |
| CY2023Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
45030000 | usd |
| CY2022Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
46310000 | usd |
| CY2024Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
1778000 | usd |
| CY2023Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
1251000 | usd |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
3607000 | usd | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
2559000 | usd | |
| CY2024Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
-1605000 | usd |
| CY2023Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
-1682000 | usd |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
-3183000 | usd | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
-3330000 | usd | |
| CY2024Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
44606000 | usd |
| CY2023Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
47081000 | usd |
| CY2024Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
44606000 | usd |
| CY2023Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
47081000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
71834000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
25559000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
46275000 | usd |
| CY2024Q2 | us-gaap |
Goodwill
Goodwill
|
21208000 | usd |
| CY2024Q2 | us-gaap |
Goodwill
Goodwill
|
21208000 | usd |
| CY2024Q2 | eols |
Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
|
93042000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
25559000 | usd |
| CY2024Q2 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
67483000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
70356000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
23246000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
47110000 | usd |
| CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
21208000 | usd |
| CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
21208000 | usd |
| CY2023Q4 | eols |
Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
|
91564000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
23246000 | usd |
| CY2023Q4 | us-gaap |
Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
|
68318000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
|
1914000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
3940000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
3530000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
3054000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
3054000 | usd |
| CY2024Q2 | eols |
Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
|
30783000 | usd |
| CY2024Q2 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
46275000 | usd |
| CY2024Q2 | us-gaap |
Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
|
842000 | usd |
| CY2023Q2 | us-gaap |
Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
|
286000 | usd |
| us-gaap |
Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
|
1477000 | usd | |
| us-gaap |
Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
|
570000 | usd | |
| CY2024Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1158000 | usd |
| CY2023Q2 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
997000 | usd |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
2312000 | usd | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1952000 | usd | |
| CY2024Q2 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
11789000 | usd |
| CY2023Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
11033000 | usd |
| CY2024Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
8351000 | usd |
| CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
13433000 | usd |
| CY2024Q2 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
4011000 | usd |
| CY2023Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
3657000 | usd |
| CY2024Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
8639000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5690000 | usd |
| CY2024Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
32790000 | usd |
| CY2023Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
33813000 | usd |
| CY2023Q2 | eols |
Debt Instrument Number Of Installments
DebtInstrumentNumberOfInstallments
|
2 | installment |
| CY2024Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
41667000 | usd |
| CY2024Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
83333000 | usd |
| CY2024Q2 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
125000000 | usd |
| CY2024Q2 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
4082000 | usd |
| CY2024Q2 | us-gaap |
Long Term Debt
LongTermDebt
|
120918000 | usd |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P5Y | |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P60M | |
| CY2023Q3 | eols |
Lessee Operating Lease Abatement Period
LesseeOperatingLeaseAbatementPeriod
|
P3M | |
| CY2023Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
4550000 | usd |
| CY2023Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
4550000 | usd |
| CY2024Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
340000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
273000 | usd |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
669000 | usd | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
547000 | usd | |
| CY2024Q2 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
35000 | usd |
| CY2023Q2 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
28000 | usd |
| us-gaap |
Variable Lease Cost
VariableLeaseCost
|
69000 | usd | |
| us-gaap |
Variable Lease Cost
VariableLeaseCost
|
62000 | usd | |
| CY2024Q2 | us-gaap |
Lease Cost
LeaseCost
|
375000 | usd |
| CY2023Q2 | us-gaap |
Lease Cost
LeaseCost
|
301000 | usd |
| us-gaap |
Lease Cost
LeaseCost
|
738000 | usd | |
| us-gaap |
Lease Cost
LeaseCost
|
609000 | usd | |
| CY2024Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P5Y7M6D | |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y7M6D | |
| CY2024Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.110 | |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.094 | |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
669000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1049000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1451000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1502000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1555000 | usd |
| CY2024Q2 | eols |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
1744000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
7970000 | usd |
| CY2024Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2136000 | usd |
| CY2024Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
5834000 | usd |
| CY2024Q2 | us-gaap |
Purchase Obligation
PurchaseObligation
|
5159000 | usd |
| CY2024Q2 | eols |
Payments For Inventory
PaymentsForInventory
|
18443000 | usd |
| eols |
Payments For Inventory
PaymentsForInventory
|
26620000 | usd | |
| CY2023Q2 | eols |
Payments For Inventory
PaymentsForInventory
|
13619000 | usd |
| eols |
Payments For Inventory
PaymentsForInventory
|
27752000 | usd | |
| CY2020Q4 | us-gaap |
Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
|
2 | complaint |
| CY2021Q4 | eols |
Loss Contingency Number Defendants Officers
LossContingencyNumberDefendantsOfficers
|
3 | officer |
| CY2020Q4 | us-gaap |
Loss Contingency Number Of Plaintiffs
LossContingencyNumberOfPlaintiffs
|
2 | plaintiff |
| CY2023Q4 | us-gaap |
Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
|
0 | usd |
| CY2024Q2 | us-gaap |
Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
|
0 | usd |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2024Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.00001 | |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2024Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2024Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
63052598 | shares |
| CY2024Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
63052598 | shares |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
4361291 | shares |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
|
0.040 | |
| CY2024Q2 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
1221491 | shares |
| CY2024Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6325383 | shares |
| CY2024Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5784000 | usd |
| CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4171000 | usd |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
10863000 | usd | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7465000 | usd | |
| CY2021Q1 | eols |
Loss Contingency Settlement Agreement Manufacturing License Period
LossContingencySettlementAgreementManufacturingLicensePeriod
|
P21M | |
| CY2021Q1 | eols |
Share Issuance Agreement Percentage Of Share Dispose Per Year Period One
ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne
|
0.25 | |
| CY2021Q1 | eols |
Share Issuance Agreement Percentage Of Share Dispose Per Year Period Two
ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo
|
0.50 | |
| CY2021Q1 | eols |
Share Issuance Agreement Percentage Of Share Dispose Per Year Period Three
ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree
|
0.75 | |
| CY2024Q2 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
4011000 | usd |
| CY2023Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
3657000 | usd |
| CY2024Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
